Your browser doesn't support javascript.
loading
A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.
King, Thomas H; Kemmler, Charles B; Guo, Zhimin; Mann, Derrick; Lu, Yingnian; Coeshott, Claire; Gehring, Adam J; Bertoletti, Antonio; Ho, Zi Z; Delaney, William; Gaggar, Anuj; Subramanian, G Mani; McHutchison, John G; Shrivastava, Shikha; Lee, Yu-Jin L; Kottilil, Shyamasundaran; Bellgrau, Donald; Rodell, Timothy; Apelian, David.
Afiliação
  • King TH; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Kemmler CB; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Guo Z; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Mann D; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Lu Y; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Coeshott C; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Gehring AJ; Molecular Microbiology and Immunology & Saint Louis University Liver Center, Saint Louis University School of Medicine, Saint Louis, Missouri, United States of America; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore.
  • Bertoletti A; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore.
  • Ho ZZ; Agency for Science, Technology and Research (A*STAR), Singapore Institute for Clinical Sciences, Singapore, Singapore.
  • Delaney W; Gilead Sciences Inc., Foster City, California, United States of America.
  • Gaggar A; Gilead Sciences Inc., Foster City, California, United States of America.
  • Subramanian GM; Gilead Sciences Inc., Foster City, California, United States of America.
  • McHutchison JG; Gilead Sciences Inc., Foster City, California, United States of America.
  • Shrivastava S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Lee YJ; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Kottilil S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Bellgrau D; GlobeImmune, Inc., Louisville, Colorado, United States of America; Integrated Department of Immunology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
  • Rodell T; GlobeImmune, Inc., Louisville, Colorado, United States of America.
  • Apelian D; GlobeImmune, Inc., Louisville, Colorado, United States of America.
PLoS One ; 9(7): e101904, 2014.
Article em En | MEDLINE | ID: mdl-25051027
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Vírus da Hepatite B / Vacinação / Hepatite B Crônica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Vírus da Hepatite B / Vacinação / Hepatite B Crônica Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article